We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App




ALT/AST Ratio Is an Independent Risk Factor for Gestational Diabetes Mellitus

By LabMedica International staff writers
Posted on 02 Feb 2022
Gestational diabetes mellitus (GDM) is defined as a state of impaired glucose tolerance first being discovered during pregnancy. More...
GDM increases the risk of pregnancy complications and adverse perinatal outcomes, such as pregnancy-induced hypertension, preeclampsia, abortion, premature delivery, premature ruptures of membranes, and large for gestational age infants.

GDM also increases the risk of type 2 diabetes (T2DM) for mother in the future and influences the metabolism of offspring in the long run, bringing both public health and economic burden. Aspartate aminotransferase-to-alanine transaminase ratio (AST/ALT) has been reported not only an assessment tool of hepatic diseases, but also a valuable prognostic tool for cardiovascular disease, arterial stiffness, cancers, and chronic kidney disease. Recently it has been of great interest as a possible novel marker for metabolic syndrome and insulin resistance.

Endocrinologists at the Peking Union Medical College Hospital (Beijing, People’s Republic of China) and their colleagues included in a prospective, double-center, observational cohort study, a total of 1,128 pregnant women. Blood samples were collected at the first prenatal visit and 75-gram oral glucose tolerance test (OGTT) was conducted for all participants during 24 to 28 weeks of gestation. Biochemical parameters presented in the present study, including ALT, AST, total bilirubin (TBil), total cholesterol (TC), triglycerides (TG), low and high density lipoprotein cholesterol (LDL-C, HDL-C), were measured by Beckman AU5800 automatic analyzer (Beckman Coulter, Brea, CA, USA). Quality controls were performed by Bio-Rad biochemical quality control product (Bio-Rad Laboratories, Hercules, CA, USA).

The investigators reported that the incidence of GDM was 22.07% (249/1,128). ALT/AST ratio was higher in GDM group than in NGT group (0.92 versus 0.80). ALT/AST had positive correlations with fasting blood glucose, 1-hour and 2-hour blood glucose concentration during OGTT (0.089, 0.176, and 0.115, respectively). The odds ratio (OR) of ALT/AST for incidence of GDM was 1.603. The ROC-AUC of ALT/AST and TG/HDL-C reached 0.615 and 0.619, respectively.

The authors concluded that higher ALT/AST in early pregnancy, even within the normal range, was an independent risk factor of GDM. ALT/AST presented similar predictive ability to TG/HDL-C for GDM in this cohort study. The study was published on January 5, 2022 in the International Journal of General Medicine.

Related Links:
Peking Union Medical College Hospital
Beckman Coulter
Bio-Rad Laboratories



New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Urine Drug Test
Instant-view® Phencyclidine Urine Drug Test
New
Uric Acid Meter
PA-16
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: Microscopy image of invasive breast cancer cells degrading their underlying extracellular matrix (Photo courtesy of University of Turku)

Visualization Tool Illuminates Breast Cancer Cell Migration to Suggest New Treatment Avenues

Patients with breast cancer who progress from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) face a significantly worse prognosis, as metastatic disease remains incurable.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.